all report title image

Muscle Spasticity Market, By Drug Type (Baclofen, Botulinum Toxin, Diazepam, Tizanidine, Dantrolene Sodium, and Others), By Route of Administration (Oral, Intramuscular, and Others), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), By Geography (North America, Latin America, Europe, Asia Pacific, Middle East & Africa)

  • Published In : 23 Jun, 2026
  • Code : CMI4827
  • Pages :256
  • Formats :
      Excel and PDF
  • Industry : Pharmaceutical
  • 역사적 분포 범위 : 2020 - 2024
  • 기준 연도 : 2025
  • 예상 연도 : 2026
  • 예측 기간 : 2026 - 2033
Ingographics Image

When muscles become stiff or contract, the condition is called as muscle spasticity. Muscle spasticity is seen in a variety of conditions such as spinal cord injury, brain injury, diseases such as amyotrophic lateral sclerosis (ALS) and multiple sclerosis (MS). It occurs when the nerve impulses involved in controlling muscle movement are either damaged or interrupted. Muscle spasticity can cause a difficulty in talking, moving, or stretching.

Symptoms of muscle spasticity include increased muscle tone, involuntary movements, abnormal posture, pain or discomfort, bone and joint deformities, decreased ability to function, and others. Spasticity should be treated when it causes pain, interferes with daily activities or sleep, or leads to decreased ability to function. Treatment given is based on the patient’s needs, preferences, and goals. The treatment includes physical therapy, occupational therapy, casting or bracing, and oral medications. Surgery may also be needed in certain cases. Oral medications are only used when the symptoms interfere with daily activities or sleep. Common medications include baclofen, dantrolene sodium, botulinum toxin, diazepam, and others.

Market Dynamics

The increasing launches of new drugs and regulatory approvals for muscle spasticity are expected to drive the market growth during the forecast period. For instance, in July 2021, Merz Therapeutics, a business of the Merz Group and a leader in the field of neurotoxins, and Teijin Pharma Limited, the core company of the Teijin Group’s healthcare business, jointly announced that Teijin Pharma was granted additional approval by Japan’s Ministry of Health, Labor and Welfare (MHLW) to market Xeomin (incobotulinumtoxinA), a neurotoxin treatment for intramuscular injection in 50, 100 or 200 units for the treatment of lower limb spasticity.

Key features of the study

  • This report provides an in-depth analysis of the global muscle spasticity market, and provides market size (US$ Mn) and compound annual growth rate (CAGR%) for the forecast period (2026–2033), considering 2025 as the base year
  • It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
  • This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends,  regional outlook, and competitive strategies adopted by key players
  • It profiles key players in the global muscle spasticity market  based on the following parameters – company highlights, products portfolio, key highlights, financial performance, and strategies
  • Key companies covered as a part of this study include Ipsen Pharma, Allergan, Acorda Therapeutics, Inc., Merz Pharma, Teva Pharmaceutical Industries Ltd., Novartis AG, Sun Pharmaceutical Industries Ltd., Beximco Pharmaceuticals Ltd., Johnson & Johnson Private Limited, Zydus Cadila, F. Hoffmann-La Roche Ltd., and Elite Pharmaceuticals Inc.
  • Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
  • The global muscle spasticity market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
  • Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global muscle spasticity market

Market Segmentation

  • By Drug Type (Revenue, USD Bn, 2021-2033)
    • Baclofen
    • Botulinum Toxin
    • Diazepam
    • Tizanidine
    • Dantrolene Sodium
    • Others
  • By Route of Administration (Revenue, USD Bn, 2021-2033)
    • Oral
    • Intramuscular
    • Others
  • By Distribution Channel (Revenue, USD Bn, 2021-2033)
    • Hospital Pharmacies
    • Retail Pharmacies
    • Online Pharmacies
  • By Region (Revenue, USD Bn, 2021-2033)
    • North America
      • U.S.
      • Canada
    • Latin America
      • Brazil
      • Mexico
      • Argentina
      • Rest of Latin America
    • Europe
      • Germany
      • U.K.
      • France
      • Italy
      • Spain
      • Russia
      • Rest of Europe
    • Asia Pacific
      • China
      • India
      • Japan
      • Australia
      • South Korea
      • ASEAN
      • Rest of Asia Pacific
    • Middle East
      • GCC
      • Israel
      • Rest of Middle East
    • Africa
      • South Africa
      • Central Africa
      • North Africa
  • Key Players
    • Ipsen Pharma
    • Allergan
    • Acorda Therapeutics, Inc.
    • Merz Pharma
    • Teva Pharmaceutical Industries Ltd.
    • Novartis AG
    • Sun Pharmaceutical Industries Ltd.
    • Beximco Pharmaceuticals Ltd.
    • Johnson & Johnson Private Limited
    • Zydus Cadila
    • Hoffmann-La Roche Ltd.
    • Elite Pharmaceuticals Inc.

Table of Contents

  1. Research Objectives and Assumptions
    • Research Objectives
    • Assumptions
    • Abbreviations
  2. Market Purview
    • Report Description
      • Market Definition and Scope
    • Executive Summary
      • Market Snapshot, By Drug Type
      • Market Snapshot, By Route of Administration
      • Market Snapshot, By Distribution Channel
      • Market Snapshot, By Region
    • Coherent Opportunity Map (COM)
  3. Market Dynamics, Regulations, and Trends Analysis
    • Market Dynamics
      • Drivers
      • Restraints
      • Opportunity
    • Impact Analysis
    • Key Highlights
    • Pipeline Analysis
    • Regulatory Scenario
    • Product Launches / Approvals
    • PEST Analysis
    • PORTER’s Analysis
    • Merger, Collaboration and Acquisitions Scenario
  4. Global Muscle Spasticity Market, By Drug Type, 2021-2033, (USD Bn)
    • Introduction
      • Market Share Analysis, 2026 and 2033 (%)
      • Y-o-Y Growth Analysis, 2022-2033
      • Segment Trends
    • Baclofen
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
    • Botulinum Toxin
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
    • Diazepam
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
    • Tizanidine
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
    • Dantrolene Sodium
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
    • Others
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
  5. Global Muscle Spasticity Market, By Route of Administration, 2021-2033, (USD Bn)
    • Introduction
      • Market Share Analysis, 2026 and 2033 (%)
      • Y-o-Y Growth Analysis, 2022-2033
      • Segment Trends
    • Oral
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
    • Intramuscular
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
    • Others
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
  6. Global Muscle Spasticity Market, By Distribution Channel, 2021-2033, (USD Bn)
    • Introduction
      • Market Share Analysis, 2026 and 2033 (%)
      • Y-o-Y Growth Analysis, 2022-2033
      • Segment Trends
    • Hospital Pharmacies
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
    • Retail Pharmacies
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
    • Online Pharmacies
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
  7. Global Muscle Spasticity Market, By Region, 2021-2033, (USD Bn)
    • Introduction
      • Market Share Analysis, By Region, 2026 and 2033 (%)
      • Y-o-Y Growth Analysis, For Regions, 2022-2033
      • Regional Trends
    • North America
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2021-2033, (USD Bn)
      • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2021-2033, (USD Bn)
      • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021-2033, (USD Bn)
      • Market Size and Forecast, and Y-o-Y Growth, By Countries, 2021-2033, (USD Bn)
        • U.S.
        • Canada
    • Latin America
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2021-2033, (USD Bn)
      • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2021-2033, (USD Bn)
      • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021-2033, (USD Bn)
      • Market Size and Forecast, and Y-o-Y Growth, By Countries, 2021-2033, (USD Bn)
        • Brazil
        • Mexico
        • Argentina
        • Rest of Latin America
    • Europe
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2021-2033, (USD Bn)
      • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2021-2033, (USD Bn)
      • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021-2033, (USD Bn)
      • Market Size and Forecast, and Y-o-Y Growth, By Countries, 2021-2033, (USD Bn)
        • U.K.
        • Germany
        • France
        • Italy
        • Spain
        • Russia
        • Rest of Europe
    • Asia Pacific
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2021-2033, (USD Bn)
      • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2021-2033, (USD Bn)
      • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021-2033, (USD Bn)
      • Market Size and Forecast, and Y-o-Y Growth, By Countries, 2021-2033, (USD Bn)
        • China
        • India
        • Japan
        • Australia
        • South Korea
        • ASEAN
        • Rest of Asia Pacific
    • Middle East
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2021-2033, (USD Bn)
      • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2021-2033, (USD Bn)
      • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021-2033, (USD Bn)
      • Market Size and Forecast, and Y-o-Y Growth, By Countries, 2021-2033, (USD Bn)
        • GCC
        • Israel
        • Rest of Middle East
    • Africa
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2021-2033, (USD Bn)
      • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2021-2033, (USD Bn)
      • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021-2033, (USD Bn)
      • Market Size and Forecast, and Y-o-Y Growth, By Region/Countries, 2021-2033, (USD Bn)
        • North Africa
        • Central Africa
        • South Africa
  8. Competitive Landscape
    • Heat Map Analysis
    • Market Share Analysis
      • Ipsen Pharma
        • Company Highlights
        • Product Portfolio
        • Key Highlights
        • Financial Performance
        • Strategies
      • Allergan
        • Company Highlights
        • Product Portfolio
        • Key Highlights
        • Financial Performance
        • Strategies
      • Acorda Therapeutics, Inc.
        • Company Highlights
        • Product Portfolio
        • Key Highlights
        • Financial Performance
        • Strategies
      • Merz Pharma
        • Company Highlights
        • Product Portfolio
        • Key Highlights
        • Financial Performance
        • Strategies
      • Teva Pharmaceutical Industries Ltd.
        • Company Highlights
        • Product Portfolio
        • Key Highlights
        • Financial Performance
        • Strategies
      • Novartis AG
        • Company Highlights
        • Product Portfolio
        • Key Highlights
        • Financial Performance
        • Strategies
      • Sun Pharmaceutical Industries Ltd.
        • Company Highlights
        • Product Portfolio
        • Key Highlights
        • Financial Performance
        • Strategies
      • Beximco Pharmaceuticals Ltd.
        • Company Highlights
        • Product Portfolio
        • Key Highlights
        • Financial Performance
        • Strategies
      • Johnson & Johnson Private Limited
        • Company Highlights
        • Product Portfolio
        • Key Highlights
        • Financial Performance
        • Strategies
      • Zydus Cadila
        • Company Highlights
        • Product Portfolio
        • Key Highlights
        • Financial Performance
        • Strategies
      • Hoffmann-La Roche Ltd
        • Company Highlights
        • Product Portfolio
        • Key Highlights
        • Financial Performance
        • Strategies
      • Elite Pharmaceuticals Inc
        • Company Highlights
        • Product Portfolio
        • Key Highlights
        • Financial Performance
        • Strategies
    • Analyst Views
  9. Section
    • Research Methodology
    • About us
  • Need a Custom Report?

    We can customize every report - free of charge - including purchasing stand-alone sections or country-level reports

    Customize Now
Logo

Credibility and Certifications

ESOMAR
DUNS Registered

860519526

Clutch
Credibility and Certification
Credibility and Certification

9001:2015

Credibility and Certification

27001:2022

EXISTING CLIENTELE

Joining thousands of companies around the world committed to making the Excellent Business Solutions.

View All Our Clients
trusted clients logo
© 2026 Coherent Market Insights Pvt Ltd. All Rights Reserved.